Vertex Pharmaceuticals (NASDAQ: VRTX) has revised its full-year 2026 revenue guidance upward following a second quarter that surpassed analyst expectations, driven largely by its cystic fibrosis (CF) franchise. The company reported quarterly revenue of $3.334 billion, a 12.5% increase year-over-year, beating the consensus estimate of $3.23 billion by roughly 3.2%. Adjusted diluted earnings per share came in at $4.73, in line with projections, while GAAP net income rose 6.5% to $1.100 billion.
Despite the upbeat headline numbers, the company's diversification efforts remain a work in progress. CF products still accounted for 96.2% of total revenue in the quarter, contributing approximately 83% of the year-over-year revenue growth. The two non-CF products, Casgevy and Journavx, generated combined sales of $126 million in Q2, up 75% sequentially, but they represent only 3.8% of overall revenue.
The raised outlook sets a challenging bar for the second half. Vertex has maintained its non-CF revenue target of at least $500 million for 2026. With first-half combined sales of Casgevy and Journavx at $197.9 million, the company needs to generate at least $302.1 million in the latter half—a 52.7% increase over the first half. This translates to an average of $151.1 million per quarter, roughly 20% above the current quarterly run rate.
Management's decision to keep the non-CF floor unchanged, while lifting the total revenue midpoint by $125 million, signals that the improved forecast is primarily driven by stronger expectations for CF products. The company also left its currency impact assumption at approximately 150 basis points and its non-GAAP tax rate at 19.5%–20.5%, both unchanged.
In the CF portfolio, the newer therapy Alyftrek continued to gain traction, adding $416.8 million in revenue year-over-year, while declines in Trikafta and legacy CF products partially offset that growth. Trikafta revenue fell 2.1% to $2.497 billion, while other CF products dropped 29.2% to $137.1 million.
Shares of Vertex closed Monday down 1.3% at $470.72, and traded roughly flat in after-hours trading. The stock remains about 11.8% below its July 7 intraday peak. At current levels, Vertex trades at a trailing P/E of 27.9x, a premium of roughly 52% compared to the average of Regeneron and Gilead, reflecting investor expectations for successful product launches and pipeline expansion.
Looking ahead, investors will be watching several catalysts. The company's proposed $10 billion acquisition of Crinetics Pharmaceuticals (NASDAQ: CRNX) is expected to close in the third quarter, with the deal valued at $8.8 billion after accounting for cash on hand. Vertex plans to finance the transaction through a combination of cash and debt, backed by $4.5 billion in bridge financing. The company has not included the acquisition in its current guidance and will revise its outlook once the deal is finalized.
Additionally, the FDA is scheduled to rule on the kidney therapy povetacicept by November 30, a potential near-term catalyst. However, risks remain: the non-CF products may fail to achieve the required momentum, CF demand could soften, and the Crinetics deal introduces funding, regulatory, and integration risks.
Vertex CEO Reshma Kewalramani emphasized the company's expanding leadership in CF while highlighting progress in blood disorders and acute pain. The company's ability to meet its ambitious non-CF targets will be a key test of its diversification strategy in the coming quarters.
